AFT Pharmaceuticals Ltd Ordinary Shares
AFT.NZXHealth Care
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.
Market Data
$3.970
+0.0%$416.4M
28.3x
$0.141
0.88%
+0.5%
Latest Earnings
AFT reports ongoing sales growth and R&D progress
7 July 2026
AFT Pharmaceuticals reports ongoing Q1 FY27 sales growth and remains on track to achieve its $300 million FY27 revenue target, supported by a full pipeline of product launches across its international business hubs. Key R&D milestones were achieved with the FDA clearing the injectable iron IND application for a Phase III trial commencing September 2026, and Japan's PMDA confirming inclusion in the study. The company also executed a new option agreement for a novel injectable formulation targeting a market exceeding US$3 billion, further strengthening its long-term growth prospects. Key points: Q1 FY27 sales growth on track to meet $300 million FY27 revenue target, underpinned by 17% average annual growth over the past two decades; FDA cleared the injectable iron IND application, enabling commencement of a global Phase III confirmatory trial in September 2026 targeting a market worth up to US$7.4 billion; Japan's PMDA confirmed inclusion in the injectable iron global study, accelerating international development; China's CDE engagement ongoing
Recent Announcements
ScomaraTM Tentative Approval by US FDA
AFT Pharmaceuticals (NZX: AFT; ASX: AFP) received tentative FDA approval for Scomara (rapamycin 0.5% cream) to treat Facial Angiofibromas in Tuberous Sclerosis, but US market launch is delayed until March 22, 2029 due to existing orphan exclusivity protection; however, AFT plans to pursue commercialization in other major markets including Canada, Australia, New Zealand, and Asia where no such restriction applies.
AFT reports ongoing sales growth and R&D progress
AFT Pharmaceuticals reports ongoing Q1 FY27 sales growth and remains on track to achieve its $300 million FY27 revenue target, supported by a full pipeline of product launches across its international business hubs. Key R&D milestones were achieved with the FDA clearing the injectable iron IND application for a Phase III trial commencing September 2026, and Japan's PMDA confirming inclusion in the study. The company also executed a new option agreement for a novel injectable formulation targeting a market exceeding US$3 billion, further strengthening its long-term growth prospects. Key points: Q1 FY27 sales growth on track to meet $300 million FY27 revenue target, underpinned by 17% average annual growth over the past two decades; FDA cleared the injectable iron IND application, enabling commencement of a global Phase III confirmatory trial in September 2026 targeting a market worth up to US$7.4 billion; Japan's PMDA confirmed inclusion in the injectable iron global study, accelerating international development; China's CDE engagement ongoing
Notice of Annual Meeting of Shareholders 2026
AFT Pharmaceuticals Limited has announced its Annual Meeting of Shareholders scheduled for Friday, 31 July 2026 in Auckland, New Zealand. The meeting will consider two ordinary resolutions: the re-election of director Marree Atkinson and authorization for the Board to fix auditor remuneration, with the Board unanimously recommending approval of both resolutions.
FDA allows AFT’s injectable iron project clinical study
This is not a stock exchange announcement but rather a BIO 2026 investor presentation by AFT Pharmaceuticals. The document discusses the company's FY26 financial results (NZ$254.7M revenue, up 22%) and R&D pipeline progress, including that the FDA has opened an IND (Investigational New Drug) application for AFT's injectable iron project with Phase III global trials planned for approximately 1,366 patients.
Capital Change Notice
AFT Pharmaceuticals Limited issued 8,400 ordinary shares at $3.46 per share on 19 June 2026 to an employee exercising options under the company's Long Term Incentive Plan, representing 0.01% of the total class of financial products.
Annual Meeting and Closing Date for Director Nominations
AFT Pharmaceuticals Limited announces its Annual Meeting of Shareholders will be held on 31 July 2026 in Auckland, New Zealand, with a director nominations closing date of 11 June 2026 at 5:00pm NZT.
issue of unlisted Options
AFT Pharmaceuticals Limited issued 495,000 unlisted options under its Long Term Incentive Plan with an exercise price of $3.49, representing approximately 0.46% of ordinary shares on issue. The options vest in three tranches subject to EBITDA performance hurdles and employee retention, with a two-year exercise period following vesting.
FY26 dividend distribution notice
AFT Pharmaceuticals Limited is distributing a fully imputed final dividend of NZD $0.025 per share (gross $0.034722) on 3 July 2026, with a total distribution value of NZD $2.62 million sourced from retained earnings.
AFT delivers double digit revenue growth and record earning
AFT Pharmaceuticals delivered a record FY26 result with revenue rising 22% to NZD $254.7 million, driven by double-digit growth across all territories including Australia (+19%), New Zealand (+11%), Asia (+41%), and International (+66%). Operating profit reached a record $24.4 million, ahead of the guidance range of $20-24 million and up 39% on FY25, while NPAT grew 24% to $14.1 million. The company issued strong FY27 guidance targeting operating profit of $28-32 million and revenue exceeding $300 million, and raised its dividend to 2.5 cents per share. Key points: Record operating profit of $24.4 million, up 39% on FY25 and ahead of guidance range of $20-24 million; Revenue grew 22% to $254.7 million with double-digit growth across all four territories: Australia (+19%), New Zealand (+11%), Asia (+41%), International (+66%); Licensing income nearly quadrupled to $3.1 million (FY25: $0.7 million), reflecting growing out-licensing momentum including a China deal for novel IV iron therapy with Grand Life Sciences Group
AFT Pharmaceuticals names Stuart Houliston CFO
AFT Pharmaceuticals announced that Stuart Houliston will commence as Chief Financial Officer on 15 June 2026, replacing Malcolm Tubby who retires on 29 May 2026. Houliston joins from Sanford and brings financial expertise from public markets and accounting (previously an audit director at KPMG).
Get real-time alerts for AFT
Receive AI-powered earnings summaries and instant notifications when AFT Pharmaceuticals Ltd Ordinary Shares releases results.
Register Free